Category: Stock Market

The S&P/ASX 200 Index (ASX: XJO) is having a tough start to the week. In afternoon trade, the benchmark index is down 1.2% to 8,416.3 points.

Four ASX shares that are falling more than most today are listed below. Here’s why they are dropping:

4DMedical Ltd (ASX: 4DX)

The 4DMedical share price is down 10% to $5.63. This may have been driven by profit-taking from some investors following a very strong gain last week. Investors were buying the respiratory imaging technology company’s shares after it made a big announcement. 4DMedical revealed that its CT:VQ technology has been deployed at the Mayo Clinic in the United States. The company’s managing director and CEO, Andreas Fouras, commented: “Mayo’s deployment is uniquely significant. When the world’s number one hospital chooses to use your technology, it sends the strongest possible signal to the entire U.S. healthcare market about the clinical value and readiness of CT:VQ.”

Brainchip Holdings Ltd (ASX: BRN)

The Brainchip share price is down 3.5% to 14 cents. Although this semiconductor company announced a licensing agreement today, the market doesn’t appear overly impressed given the customer and the terms. BrainChip has entered into a technology licensing deal with Korea-based semiconductor company EDGEAI for its Akida 2 neuromorphic IP. The company will receive unspecified payments as it provides various deliverables, including IP access, engineering support, and integration services, as well as royalties on product sales. The agreement is global and non-exclusive, meaning EDGEAI is not restricted from working with other technology providers. In addition, it can be terminated by the customer without cause on one month’s notice.

Catapult Sports Ltd (ASX: CAT)

The Catapult Sports share price is down 14% to $2.92. This follows the release of the sports technology company’s analyst day presentation. Catapult revealed bold growth ambitions, targeting a rise in average annual contract value (ACV) per pro team from US$20,000 to between US$100,000 and US$150,000. However, this will depend on successful upselling to existing teams and launching additional products.

Star Entertainment Group Ltd (ASX: SGR)

The Star Entertainment share price is down 2% to 12.25 cents. This morning, this casino and resorts operator revealed that it has entered into a binding commitment letter with funds associated with WhiteHawk Capital Partners. This is in relation to a refinancing of its debt. It notes that the annual interest rate based on the term SOFR plus a margin that is materially consistent with its recent facility agreements.

The post Why 4DMedical, Brainchip, Catapult, and Star Entertainment shares are falling today appeared first on The Motley Fool Australia.

More reading

• Why are Catapult shares tumbling 13% on Monday?
• What’s going on with BrainChip shares today?
• Catapult Group targets bigger ACV per team
• 5 things to watch on the ASX 200 on Monday
• What’s Bell Potter’s updated view on Catapult shares after its earnings results?

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Catapult Sports. The Motley Fool Australia has positions in and has recommended Catapult Sports. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

After a brutal two-day sell-off last week, shares in Dateline Resources Ltd (ASX: DTR) are frozen on Monday.

This comes as the market waits for details of a fresh capital raising.

The ASX granted the trading halt following the company’s request for time to finalise the proposed funding announcement.

Dateline shares last traded at 45.5 cents, down 10.78% on Friday after already falling 8.11% in the prior session. That rapid pullback interrupted what has otherwise been a huge run in 2026, with the stock still sitting up more than 100% since the start of the year.

Trading is expected to resume by Wednesday morning unless the company releases the raising details sooner.

Here’s what has triggered the halt.

Funding details now become the key focus

Today’s ASX release confirms the halt is tied to a proposed material capital raising, with management using the pause to finalise terms.

At this stage, the company has not disclosed the size of the raising, the issue price, or whether existing shareholders will be able to participate.

Those details are now likely to determine the direction of the share price when trading resumes.

The biggest question for the market is how aggressively the new shares are priced relative to Friday’s close of 45.5 cents.

A steep discount would raise the risk of short-term selling pressure, particularly after last week’s significant decline.

That backdrop may also explain why the stock was already weakening into the halt, with some traders potentially anticipating a funding update.

The bigger picture behind the 2026 rally

Even with the latest sell-off, Dateline remains one of the ASX’s strongest performers this year.

The stock is still up more than 100% in 2026, supported by growing market interest in its 100%-owned Colosseum Gold and Rare Earths Project in California.

That asset has become the central driver of the company’s re-rating, particularly as investors look for exposure to US-based gold and strategic minerals projects.

Because of that, the market’s reaction to the raising is likely to depend heavily on where the funds are going.

If the capital is directed toward drilling, resource upgrades, permitting, or development work at Colosseum, shareholders may be more willing to absorb the dilution.

The market has already shown it is willing to support the stock when there’s clear progress at the project.

Foolish Takeaway

The trading halt has shifted the focus from last week’s heavy selling to what Dateline announces next.

After falling nearly 18% across two sessions, attention now turns to the pricing and purpose of the raising. This will likely determine whether the recent weakness is temporary or the start of a broader downtrend.

Nonetheless, the stock is still holding onto triple-digit gains for 2026. That could help support sentiment if the new funds are directed towards further developing its flagship California project.

The post This ASX stock is halted after plunging nearly 18% in 2 sessions appeared first on The Motley Fool Australia.

More reading

• Up 100% in 2026, this ASX stock just dropped 8%. Here’s why
• This ASX mining stock has surged 10,000%: Is there more to come?
• This ASX mining stock just jumped again. Here’s what it announced today
• This ASX rare earths stock is rocketing 13% on big news

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Pro Medicus Ltd (ASX: PME) shares are tumbling today.

Shares in the S&P/ASX 200 Index (ASX: XJO) health imaging company closed Monday trading for $117.70. During the Monday lunch hour, shares are changing hands for $112.46 apiece, down 4.5%.

For some context, the ASX 200 is down 1.4% at this same time.

Unfortunately for longer-term stockholders, today’s underperformance has been more the rule than the exception over the past eight months.

Indeed, Pro Medicus shares are now down a painful 66.0% since notching an all-time closing high of $330.48 on 17 July last year.

That comes despite the company posting some strong financial growth metrics in H1 FY 2026, as investor fears over potentially rising competition from AI models has intensified this year.

But after this sharp sell down, two top analysts believe the ASX 200 healthcare stock is well-placed to rebound (courtesy of The Bull).

Should you buy Pro Medicus shares today?

“Pro Medicus develops advanced medical imaging software used by major hospitals and radiology groups globally,” said Catapult Wealth’s Blake Halligan

Citing the first reason he has a buy recommendation on Pro Medicus shares, Halligan said, “The company reported a strong first half result in fiscal year 2026, with revenue up 28.4% to $124.8 million and underlying profit before tax rising 29.7% to $90.7 million.”

Then there’s the company’s strong balance sheet and recent new contract wins.

According to Halligan:

In March, PME secured two important contract renewals worth a minimum of $40 million, both at higher transaction fees, signalling strengthening pricing power. With an underlying earnings before interest and tax margin at 73% and cash of $222 million, PME remains financially robust.

And the third reason you might want to buy the ASX 200 healthcare share today is the company’s positive growth prospects in the massive US healthcare market.

“Growing US market share supports a positive long term growth outlook, making PME an attractive portfolio addition,” Halligan concluded.

Also tipping the ASX 200 healthcare share as a buy

MPC Markets’ Mark Gardner also has a bullish outlook on the beaten down Pro Medicus shares.

“The company provides medical imaging software and services to hospitals and healthcare groups across the world,” said Gardner. “Its software has quietly become the dominant choice across some of the largest hospital networks in the United States.”

And rather than expressing concern over the potential impact of AI, Gardner believes it will help the company’s growth prospects.

“The product is faster, more scalable and modern than what its competitors offer. Artificial intelligence is built in, so it complements the business,” he said.

Summing up his buy recommendation on the ASX 200 stock, Gardner concluded:

The share price plunge has been driven by broad technology sentiment as opposed to issues with the business. Earnings are still growing and the company still wins major new hospital contracts.

In our view, the market has handed investors an appealing entry point into one of the best software businesses on the ASX. We retain our buy recommendation.

The post 3 reasons to buy Pro Medicus shares today appeared first on The Motley Fool Australia.

More reading

• 3 ASX 200 shares that could beat the market over the next 10 years
• How to become a millionaire with a $5,000 investment in ASX 200 shares each year
• Top Australian shares to buy right now with $2,500
• Down 65%: Are Pro Medicus shares in the buy zone yet?
• Where to invest $10,000 in ASX shares right now

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a disappointing decline. At the time of writing, the benchmark index is down 1.35% to 8,402 points.

Four ASX shares that are not letting that hold them back are listed below. Here’s why they are rising:

AMP Ltd (ASX: AMP)

The AMP share price is up 4% to $1.30. Investors have been buying the financial services company’s shares after it announced an on-market share buyback. AMP advised that it will begin buying back up to $150 million of ordinary shares on-market following the release of its first quarter update next month. AMP’s chief executive, Alexis George, said: “We remain committed to returning surplus capital to shareholders in the absence of a compelling alternative, and prioritising organic growth in our wealth businesses. Today’s announcement demonstrates this, with an on-market share buyback the most efficient use of capital at this time.”

Greatland Resources Ltd (ASX: GGP)

The Greatland Resources share price is up almost 8% to $10.51. This has been driven by an update from the gold miner this morning. Greatland Resources revealed a 150% increase in the Telfer project’s gold mineral resources to 8.0 million ounces. This means that the combined Telfer and Havieron resources now total 14.9 million ounces of gold and 645,000 tonnes of copper. The company’s managing director, Shaun Day, said: “Telfer and Havieron’s combined resource of 550Mt @ 0.84g/t Au & 0.12% Cu for 14.9Moz Au & 645Kt Cu has the potential to underpin a multi-decade, world class mining hub. Our investment in significantly increased drilling has delivered substantial organic growth, with the overall Telfer resource growing by 150% to 8.0Moz, and the higher confidence Measured and Indicated component by 163% to 3.8Moz.”

Minerals 260 Ltd (ASX: MI6)

The Minerals 260 share price is up 5% to 63.2 cents. This follows the release of further positive results from the ongoing drilling program at its 100% owned 4.5Moz Bullabulling Gold Project in Western Australia. Commenting on the results, Minerals 260’s managing director, Luke McFadyen, said: “Drilling results received since the December 2025 MRE continue to reinforce our confidence in the growth potential of the MRE. The current program is focused on both expanding the resource and upgrading classifications, particularly within shallow areas targeted for early mining, while also testing high-priority extension targets at depth and along strike.”

Woodside Energy Group Ltd (ASX: WDS)

The Woodside Energy share price is up 3% to $35.43. Investors have been buying Woodside and other ASX energy shares today after oil prices surged on Friday night. This was in response to escalating tensions in the Middle East. The S&P/ASX 200 Energy index is up 2.9% at the time of writing.

The post Why AMP, Greatland Resources, Minerals 260, and Woodside shares are pushing higher today appeared first on The Motley Fool Australia.

More reading

• Why is this ASX gold stock storming 10% higher today?
• AMP shares charge higher on Monday despite market selloff: What’s going on?
• Greatland Resources delivers major resource upgrade at Telfer
• 5 things to watch on the ASX 200 on Monday
• ASX 200 mining shares rebound after March sell-off creates opportunities

Motley Fool contributor James Mickleboro has positions in Woodside Energy Group Ltd. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

It’s been a tough session for investors in Catapult Group International Ltd (ASX: CAT) shares.

The Catapult share price tumbled 12.9% to $2.97 during early afternoon trade, adding to what has already been a painful period for investors.

The ASX technology stock is now down 28.6% year to date and has plunged roughly 57% over the past six months.

So, what’s behind the latest sell-off?

Lifting the bar

The weakness of Catapult shares comes as the sports technology company outlined its strategy to grow average annual contract value (ACV) per professional team — and while the long-term vision is ambitious, it may have raised some near-term concerns.

At its core, Catapult provides performance analytics and wearable tracking technology to professional sports teams. Its solutions help teams monitor athlete performance, reduce injury risk, and gain a competitive edge through data.

Now, management is aiming much higher. The company is targeting a significant increase in average ACV per pro team, lifting it from around US$20,000 today to between US$100,000 and US$150,000 over time. That’s a massive jump — and it will rely heavily on upselling, cross-selling, and rolling out new products.

There’s a catch: Execution risk

The strategy is built around a “land and expand” model. Catapult plans to win new customers with its core performance and health (P&H) offerings, then deepen those relationships by layering on additional features and solutions. On paper, it’s a compelling approach.

Catapult appears focused on boosting the value it delivers to each customer, rather than just chasing new sign-ups. By turning smaller initial contracts into broader, multi-solution partnerships, the company could unlock meaningful revenue growth without needing to dramatically expand its customer base.

Investors may be questioning how quickly and how easily Catapult can scale ACV to those ambitious targets. Upselling existing customers and convincing teams to adopt multiple products isn’t guaranteed. It’s particularly difficult in a competitive and budget-conscious environment.

Catapult shares snapshot

That uncertainty comes at a time when Catapult shares are already under pressure and near recent lows. When expectations are high and delivery is still ahead, the market can be quick to hit the sell button.

Looking at the bigger picture, the recent decline has been significant. Over the past 12 months, Catapult shares are down 14%, underperforming the S&P/ASX 200 Index (ASX: XJO), which has risen around 5.3% over the same period.

The bottom line? Catapult’s long-term growth strategy could be powerful if it works. Right now, investors appear wary about the path to get there.

The post Why are Catapult shares tumbling 13% on Monday? appeared first on The Motley Fool Australia.

More reading

• Catapult Group targets bigger ACV per team
• 5 things to watch on the ASX 200 on Monday
• What’s Bell Potter’s updated view on Catapult shares after its earnings results?
• 3 bargain ASX tech shares I’d buy right now
• Why Catapult, DroneShield, Infratil, and Qoria shares are charging higher today

Motley Fool contributor Marc Van Dinther has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Catapult Sports. The Motley Fool Australia has positions in and has recommended Catapult Sports. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Macquarie Group Ltd (ASX: MQG) share price has been feeling pain in the last few weeks, just like many other stocks. But, experts are optimistic that the ASX financial share could deliver good returns over the next 12 months.

Macquarie is one of the most diversified businesses on the ASX, particularly in the financial sector, due to the varied operations of its segments and how it has a global earnings base.

Impressively, it makes around two-thirds of its money internationally, which I think is a powerful tool because it reduces the risk of being too focused on one region, and it also means it can look across the world for the best places to invest for growth.

Additionally, I also like how it has four different areas of its business – investment banking (Macquarie Capital), asset management (Macquarie Asset Management (MAM)), banking and financial services (BFS), and commodities and global markets (CGM).

The company has a variety of ways of making a profit and looking for further growth avenues. Due to this, I prefer Macquarie over the major ASX bank shares.

With its global and diversified earnings base in mind, I think it’s well-placed to navigate the current volatile markets.

Let’s take a look at what experts think could happen to the ASX financial share in the coming months.

Exciting Macquarie share price target

A price target tells investors where experts believe the share price will be trading in 12 months from the time that they make that analysis call, taking into account the company’s earnings trajectory and other elements worth considering with the valuation.

According to CMC Invest, there are five recent buy ratings (and four hold ratings) on the business.

Of those nine ratings, the average price target is $228.95. That suggests a possible rise of more than 17% over the next year, from where it is at the time of writing.

The latest update from the business was for the FY26 third quarter, for the three months to December 2025, which showed positive year-over-year growth for the business.

It reported for that quarter that the MAM net profit was “substantially up”, BFS net profit was “slightly up”, CGM net profit was “substantially up” and Macquarie Capital net profit was “substantially up”.

While one quarter’s performance isn’t the whole financial year, nor is it necessarily reflective of how earnings will perform during 2026, I think it’s a good sign for Macquarie and shows it can deliver strong growth at times.

I’m particularly impressed by the level of deposit and loan growth at Macquarie’s BFS – they grew 6% and 7%, respectively, quarter over quarter. That’s a great growth rate and could help Macquarie become a ‘big 5’ bank in Australia in the coming years.

The post How much could the Macquarie share price rise in the next year? appeared first on The Motley Fool Australia.

More reading

• Hub24 vs Netwealth: Which ASX tech stock is the better buy now?
• How to invest $10,000 in ASX dividend shares in 2026
• What could $500 a month in ASX 200 shares become in 20 years?
• ASX bank stocks: Buy, sell, or hold?
• How to build $100,000 a year in passive income from ASX shares

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Macquarie Group. The Motley Fool Australia has positions in and has recommended Macquarie Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

BHP Group Ltd (ASX: BHP) shares are edging lower today.

Shares in the S&P/ASX 200 Index (ASX: XJO) mining giant closed on Friday trading for $50.37. In morning trade on Monday, shares are swapping hands for $50.24, down 0.3%.

For some context, the ASX 200 is down 1.5% at this same time.

Taking a step back, BHP shares have strongly outperformed over the past year, gaining 31.5% compared to the 7.4% 12-month gains posted by the benchmark index. BHP also paid out two fully franked dividends over the year totalling (a rounded) $1.96 a share.

However, since the onset of the Middle East conflict, the Aussie mining giant has underperformed. Shares have fallen 15.2% since market close on 2 March, trailing the 8.8% losses posted by the ASX 200.

Which, according to Sanlam Private Wealth’s Remo Greco, could make now an opportune time to pick up some shares in the ASX 200 miner at a bargain (courtesy of The Bull).

Should you buy BHP shares today?

“The current volatility presents investors with an opportunity to buy this global miner at attractive prices,” said Greco, citing the first reason he’s bullish on BHP shares.

As for the second reason, he noted:

The recent BHP announcement of Brandon Craig replacing the retiring Mike Henry as chief executive is a good appointment. Craig was responsible for the company’s Americas business, and that’s where the growth is likely to come from in the medium term.

BHP shares closed up 0.7% on 18 March, the day the miner announced Craig’s elevation to CEO.

And the third reason you might want to buy the ASX 200 mining giant today is its growing revenues and profits.

“Group revenue in the first half of 2026 was up 11% on the prior corresponding period and profit from operations was up 34%,” Greco said.

A modestly less bullish view

MPC Markets’ Mark Gardner also recently analysed the outlook for BHP shares.

While he also sounded an optimistic note, Gardner currently has a hold recommendation on the ASX 200 mining stock.

According to Gardner:

The global miner delivered a strong half year result in fiscal year 2026. Copper delivered the majority of earnings for the first time in the company’s modern history. The dividend was above expectations. The balance sheet is in good shape.

The conflict in Iran has rattled commodity markets, and BHP shares have fallen heavily. Most of BHP’s output goes to Asia, not through the Strait of Hormuz. The market is selling the ticker, not the fundamentals.

We suggest adding on weakness, and holding for an upgrade when the conflict ends.

The post 3 reasons to buy BHP shares today appeared first on The Motley Fool Australia.

More reading

• ASX 200 mining shares rebound after March sell-off creates opportunities
• How many BHP shares do I need to $1,000 of passive income?
• Would I buy BHP, CBA, and CSL shares today?
• 3 top Vanguard ETFs I would buy in April
• How I’d invest $20,000 in ASX shares right now to help build long-term wealth

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended BHP Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Shares in KMD Brands Ltd (ASX: KMD) remain in a trading halt four business days after the company first asked that trading be halted, amid rumours that it is struggling to finalise a capital raise.

The retail brands owner, which operates the Rip Curl and Kathmandu brands, first asked that its shares be placed in a trading halt on March 25, saying it was planning to raise new capital, as well as release its first-half results to the market.

The original trading halt was meant to be in place until Friday.

The company said at the time:

KMD notes that it is effectively conducting an extended book build for a private placement, and there is a risk of material information leaking ahead of the formal announcement of the capital raise. KMD is not presently in a position to make a further announcement regarding the capital raise as the final details are still being determined.

On Friday, the company asked that the suspension of its shares be extended to Monday morning, but then on Monday, it asked for a voluntary suspension of its shares until Tuesday morning.

The company also said at this time it was looking to refinance its existing bank facilities.

While the company has not given any hint as to the size of the capital raise, The Australian was reporting on Monday that KMD was after about NZ$100 million, but was struggling to secure that number, with only about NZ$30 million in commitments so far raised.

The Australian report said that the company was looking to raise funds in the form of preferred securities, which combine features of both equity and debt.

Recent transaction rejected

KMD Brands also last week rejected a deal from US company Stokehouse to buy Rip Curl.

That deal would have involved demerging Rip Curl into a separate entity to be listed on the Australian and New Zealand share markets.

KMD said regarding the proposed deal:

Stokehouse proposed that after the de-merger of Rip Curl from KMD Brands, and its merger with Stokehouse, Stokehouse shareholders would own 22% of the merged entity. This proposed ownership structure is misaligned with the earnings delivered by the Stokehouse and Rip Curl businesses given Stokehouse’s immaterial contribution to combined EBITDA, and would unfairly dilute KMD Brands shareholders. In addition, Mr. Naude, the current CEO of Stokehouse, would be Chief Executive of the combined business, and he would lead the business from California.

KMD Brands shares last changed hands for 15.5 cents, which was a 12-month low for the stock.

The company is valued at $110.3 million.

The post What’s going on with KMD Brands shares? appeared first on The Motley Fool Australia.

More reading

• Trading halt, delayed results, and a capital raise: Why this ASX retail stock is under pressure
• Which ASX retail company just rejected a deal to buy its Rip Curl stores?

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The S&P/ASX 200 Index (ASX: XJO) is down 1.5% on Monday, with these five ASX 200 shares falling to new 52-week-plus lows.

Two of the underperforming companies are in the technology sector, two are in healthcare, while the fifth is a major property developer.

Here’s what’s happening.

Two ASX 200 tech shares dropping to fresh one-year-plus lows

The first company making this rather ignominious list today is WiseTech Global Ltd (ASX: WTC).

Shares in the logistics software solutions company are down 5.1% in late morning trade today, changing hands for $36.42 each. That sees the WiseTech share price down 55.2% over 12 months and trading at its lowest level since June 2022.

WiseTech shares have come under pressure over the past months amid increasing concerns that artificial intelligence (AI) could soon be able to deliver much of the same services the company offers at materially cheaper costs.

Which brings us to the second ASX 200 share trading at 52-week-plus lows today, Xero Ltd (ASX: XRO).

Shares in the business and accounting software provider are down 4.9% at the time of writing, trading for $69.25 apiece. This puts the Xero share price down 55.3% over 12 months and trading at its lowest level since November 2022.

Like WiseTech, Xero shares are facing negative investor sentiment amid the rapid rise of AI technologies.

Two ASX 200 healthcare shares sinking to new 52-week lows

Moving on to the healthcare space, we have Sigma Healthcare Ltd (ASX: SIG).

Shares in the retail pharmacy giant, which merged with Chemist Warehouse in 2025, are down 0.6% today, trading for $2.605 each. That sees the Sigma Healthcare share price down 9.6% in a year and at its lowest level since December 2024, prior to the merger.

ResMed Inc (ASX: RMD) shares are also doing it tough.

Shares in the sleep disorder treatment company are down 1.3% today, changing hands for $31.925 each. That puts this ASX 200 share down 8.7% over 12 months and trading at its lowest level since August 2024.

As for the property development giant…

Interest rates may be biting

Stockland Corp Ltd (ASX: SGP) shares join our list of stocks slumping to new one-year-plus lows today.

Shares in the diversified property development company are down 1.4% on Monday, trading for $4.20 each. That puts this ASX 200 share down 14.3% over 12 months and trading at its lowest level since January 2025.

Like many real estate companies, Stockland shares have faced headwinds amid resurgent global inflation and expectations of higher interest rates to come. Real estate stocks tend to perform better in low and falling interest rate environments.

The post 5 ASX 200 shares including WiseTech and Xero plumbing new 52-week-plus lows on Monday appeared first on The Motley Fool Australia.

More reading

• Got $5,000 to invest? Here are 2 ASX tech stocks to buy today
• 2 ASX shares highly recommended to buy: Experts
• How I’d aim to build a $100,000 ASX share portfolio starting at zero
• 3 ASX 200 shares that could beat the market over the next 10 years
• How to become a millionaire with a $5,000 investment in ASX 200 shares each year

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed, WiseTech Global, and Xero. The Motley Fool Australia has positions in and has recommended ResMed, WiseTech Global, and Xero. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

BrainChip Holdings Ltd (ASX: BRN) shares are on the slide on Monday morning.

At the time of writing, the ASX tech stock is down 3.5% to 14 cents.

Why are Brainchip shares falling today?

The company’s shares are falling today despite the release of an announcement revealing a long-awaited licensing agreement.

According to the release, BrainChip has entered into a technology licensing deal with Korea-based semiconductor company EDGEAI for its Akida 2 neuromorphic IP.

The agreement will see BrainChip provide access to its technology, along with integration support and development tools, to assist EDGEAI in incorporating Akida into its future products.

What is it worth?

The company hasn’t been able to place a dollar figure on the estimated value of the agreement.

It notes the commercial structure of the agreement is tied to the delivery of technical milestones.

BrainChip will receive unspecified payments as it provides various deliverables, including IP access, engineering support, and integration services.

In addition, the company is eligible to receive royalties based on future product sales from EDGEAI that incorporate its technology. These royalties would only be payable once commercial shipments commence.

Furthermore, any potential royalty stream will be dependent on the success of EDGEAI’s products in the market, which is a very large unknown. This is particularly the case given that EDGEAI isn’t a proven name in the semiconductor industry.

In fact, rather embarrassingly, EDGEAI’s website has gone offline today after exceeding its traffic quota.

Flexible terms

It is also worth highlighting that the agreement is global and non-exclusive, meaning EDGEAI is not restricted from working with other technology providers.

In addition, the licence remains in place only while EDGEAI continues to use the Akida IP and can be terminated by the customer without cause on one month’s notice.

Brainchip’s CEO, Sean Hehir, said:

We are excited to partner with EDGEAI as they bring their next generation AI solutions to market. This agreement reflects the growing global demand for neuromorphic computing and the unique advantages delivered by our Akida technology. Together, we are enabling smarter, more efficient edge devices that can operate with exceptionally low power while supporting sophisticated on device intelligence.

Foolish takeaway

While today’s announcement represents progress in commercialising its technology, the financial contribution from the deal remains uncertain at this stage.

With milestone-based payments and royalties dependent on future product success, the extent to which this agreement translates into meaningful revenue will become clearer over time.

The post What’s going on with BrainChip shares today? appeared first on The Motley Fool Australia.

More reading

• Sell alert! Why this expert is calling time on Nuix and Brainchip shares
• Buy, hold, sell: Brainchip, CAR Group, and Endeavour shares